drugset
drugset / Trial / NCT03510767

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

NCT03510767 ↗

Phase 1 Unknown 60 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To study the pharmacokinetic characteristics of TQ-B3525 in the human body, recommend a reasonable regimen for subsequent research.

Timeline

Start
2018-06-20
Primary completion
2022-08-15
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Subject TQ-B3525 Small molecule — Oral

Indications

lymphoma